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Background: Obesity is an independent adverse prognostic factor in early breast cancer patients, but it is still controversial
whether obesity may affect adjuvant endocrine therapy efficacy. The aim of our study (ancillary to the two clinical trials Gruppo
Italiano Mammella (GIM)4 and GIM5) was to investigate whether the circulating oestrogen levels during treatment with the
aromatase inhibitor letrozole are related to body mass index (BMI) in postmenopausal women with breast cancer.
Methods: Plasma concentration of oestrone sulphate (ES) was evaluated by radioimmunoassay in 370 patients. Plasma samples
were obtained after at least 6 weeks of letrozole therapy (steady-state time). Patients were divided into four groups according to
BMI. Differences among the geometric means (by ANOVA and ANCOVA) and correlation (by Spearman’s rho) between the ES
levels and BMI were assessed.
Results: Picomolar geometric mean values (95% confidence interval, n¼patients) of circulating ES during letrozole were 58.6
(51.0–67.2, n¼ 150) when BMI was o25.0 kgm 2; 65.6 (57.8–74.6, n¼ 154) when 25.0–29.9 kgm 2; 59.3 (47.1–74.6, n¼ 50) when
30.0–34.9 kgm 2; and 43.3 (23.0–81.7, n¼ 16) when X35.0 kgm 2. No statistically significant difference in terms of ES levels
among groups and no correlation with BMI were observed.
Conclusions: Body mass index does not seem to affect circulating oestrogen levels in letrozole-treated patients.
High body mass index (BMI) is associated with a significant
increased incidence of postmenopausal breast cancer
(Carpenter et al, 2003; Eliassen et al, 2006; Reeves et al, 2007;
Vrieling et al, 2010; Key et al, 2011) and with an increased
risk of breast cancer recurrence and mortality in patients with a
previous diagnosis of breast cancer (Ewertz et al, 2011; Sparano
et al, 2012).
Obese postmenopausal women may have an increased oestrogen
synthesis, mediated by the enzyme aromatase (Miller, 2006), which
leads to higher levels of circulating oestrogens compared with women
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of similar age but with normal BMI (Judd et al, 1974). The high levels
of circulating oestrogens could explain the inferior outcome observed
in obese hormone receptor-positive breast cancer women (Sparano
et al, 2012) compared with non-obese. While obesity at diagnosis is
known to be an independent adverse prognostic factor in early-stage
breast cancer, it is still unknown whether obesity may affect the
efficacy of adjuvant endocrine therapy.
The association between clinical outcome and BMI in both
advanced and early breast cancer treated with aromatase inhibitors
is still controversial (Schmid et al, 2000; Michaud et al, 2002; Sestak
et al, 2010; Seynaeve et al 2010; Pfeiler et al, 2011; Ewertz et al,
2012; Wolters et al, 2012). In advanced breast cancer, it was
reported that obese patients benefited significantly less from
letrozole treatment than thin women (Schmid et al, 2000). On the
other hand, Michaud et al (2002) found that the efficacy of
anastrozole did not depend on BMI. In the adjuvant setting,
treatment with anastrozole was associated with a lower recurrence
rate as compared with tamoxifen, regardless of the BMI, but its
benefit was greater in thinner women (Sestak et al, 2010). The
subgroup analysis of the German BRENDA cohort showed a
significantly shorter recurrence-free survival in postmenopausal
obese patients, who tended to benefit more from tamoxifen than
from aromatase inhibitors (Wolters et al, 2012).
On the other hand, data from the Tamoxifen Exemestane
Adjuvant Multinational (TEAM) trial showed no differences in
disease recurrences between obese women treated with tamoxifen and
those treated with exemestane (Seynaeve et al, 2010), and results from
the Breast International Group 1–98 Trial indicated that letrozole
clinical efficacy was not associated with BMI (Ewertz et al, 2012).
Here, we investigate the correlation between BMI and the activity
(evaluated through plasma concentration of oestrone sulphate
(ES)) of the aromatase inhibitor letrozole in early breast
cancer postmenopausal women, who were in adjuvant endocrine
treatment.
PATIENTS AND METHODS
Patients. Postmenopausal women with radically resected early
breast cancer (defined as tumours that are T1-2, N0-1, M0 according
to TNM staging system), oestrogen receptor (ER)-positive and/or
progesterone receptor (PR)-positive (considering positive every
values ofX1%) were enrolled into this study between 2005 and 2008.
Main inclusion criteria for the Gruppo Italiano Mammella
(GIM)4 and GIM5 studies were
(A) Stage I–III, histologically proven ER-positive and/or PR-
positive breast cancer;
(B) Definitive surgical treatment (either mastectomy or breast
conserving surgery) and axillary or sentinel node dissection;
(C) Previous adjuvant hormonal therapy with tamoxifen for 2–3
years (GIM4 study) or at least 4½ years and not more than 6
years (GIM5 study). Tamoxifen had to be completed not more
than 6 months before study entry;
(D) Postmenopausal status defined as: (i) age 455 years
with cessation of menses or (ii) age o55 years but not
spontaneous menses for X1 year, or (iii) age o55 years
and spontaneous menses within the previous 12 months,
but currently amenorrheic (e.g., spontaneous, or secondary
to hysterectomy), and with postmenopausal gonadotropin
levels (luteinising hormone and follicle-stimulating hormone
levels 440 IU l 1) and postmenopausal oestradiol levels
(o5 ng dl 1) or according to the definition of ‘postmeno-
pausal range’ for the laboratory involved;
(E) Eastern Cooperative Oncology Group (ECOG) Performance
Status p2;
(F) Adequate bone marrow, liver and kidney function.
Study design. This study is a part of two prospective, multicentre,
not blinded, studies of adjuvant hormonal therapy for early breast
cancer patients: GIM4 and GIM5 studies.
The GIM4 study (LEAD study, LEtrozole Adjuvant Duration) is
a phase III, multicentre randomised study that evaluates the
optimal duration of adjuvant hormonal therapy with letrozole in
postmenopausal women diagnosed with early breast cancer treated
with 2–3 years of tamoxifen: after 2–3 years of tamoxifen
treatment, patients were randomised either to receive letrozole
up to a total duration of the endocrine treatment of 5 years or to
receive letrozole for an additional 5 years regardless of the duration
of the previous tamoxifen treatment (Clinical trial.gov identifier:
NCT01064635).
The GIM5 study (CYPLEC study) is a multicentre, prospective,
non-randomised study of adjuvant hormonal therapy with
letrozole in women diagnosed with early breast cancer patients
after 4½ to 6 years of tamoxifen that provides a genetic analysis of
CYP19 gene, plasma evaluation of letrozole and ES before and
during letrozole treatment (EudraCT n. 2005-001213-18) (Lunardi
et al, 2013).
A subgroup of patients from five centres, participating in both
GIM4 and GIM5 studies, were enrolled in this ancillary study. The
aim was to evaluate the association between ES levels and BMI in
postmenopausal women diagnosed with breast cancer receiving
treatment with letrozole (Femara; Novartis, Basel, Switzerland)
2.5mg daily.
For this ancillary study on ES levels and obesity, patients had to
be on treatment with letrozole for at least 6 weeks (i.e., at the time
of letrozole steady state).
The studies were approved according to Italian national
regulations. Written informed consent was obtained from each
subject before the beginning of protocol-specific procedures,
according to institutional procedures and to the declaration of
Helsinki. Each patient received letrozole 2.5mg daily, provided by
medical oncology departments. Physical examination and compli-
ance (patients were questioned to confirm compliance and the
number of tablets were accounted for) were assessed every 3 months.
Hormone measurements. The use of plasma oestrogens (oestra-
diol and oestrone) to evaluate the activity of aromatase inhibitors is
hampered by technical difficulties in measuring very low
postmenopausal oestrogen levels (Geisler et al, 2002, 2008; Dixon
et al, 2008). This is a minor problem with ES, whose levels are
measurable by highly sensitive assay methods also in postmeno-
pausal women. Plasma ES is produced by sulfatation of circulating
oestrone and the levels of oestradiol, oestrone and ES are in
equilibrium (Lønning and Ekse, 1995).
Samples were collected in five Italian medical oncology
departments. Medical oncologists of each centre were adequately
instructed about sample collection and storage.
Blood samples for hormone measurements were collected in
vials containing sodium EDTA between 0800 and 1000 h to avoid
circadian variations. Blood samples were collected after no less
than 6 weeks (i.e., at the time of letrozole steady state; Lønning
et al, 2003), from the beginning of letrozole treatment. Plasma
samples were separated by centrifugation and stored at  80 1C
until analysis that was performed, on average, within 6 months.
Estrone sulphate levels were determined by a commercially
available (DSL-5400 Diagnostic Systems Laboratories Inc.,
Webster, TX, USA) radioimmunoassay (RIA) after a non-
chromatographic procedure to eliminate interferences from
dehydroepiandrosterone sulfate (DHEAS) (Brind et al, 1990)
according to a validated method (Lunardi et al, 2013) described
previously.
Assay sensitivity was 14 pM l 1 (CVo14%) and was calculated by
the instrument (gamma-scintillation counter Cobra II Autogamma;
Canberra Packard, Central Europe GmbH, Schwadorf, Austria).
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Values below this limit were used for calculation of the means and
they were assigned half the value of the lower limit of
quantification (Hornung and Reed, 1990).
BMI definition. Body mass index was calculated by the formula:
weight/height2 (kgm 2). According to the World Health
Organization classification (http://www.who.int/bmi/index.jsp;
3 August 2012), patients were divided into four groups according
to their BMI value: lower than 25.0; from 25.0 to 29.9; from 30.0 to
34.9 and higher than 35.0. In accordance with the World Health
Organization, a BMI of greater than 25.0 kgm 2 indicates
overweight, a BMI from 30.0 to 34.9 kgm 2 indicates obesity
and a value of greater than 35.0 kgm 2 indicates severe obesity.
Statistical methods. Plasma levels of ES were evaluated through a
logarithmic normal distribution (ln) (Lønning et al, 1995), and
these values of ES were utilised for statistical analyses. Geometric
means and 95% confidence intervals were used as summary
measures.
To assess the difference between the geometric means, the
ANOVA and the ANCOVA (adjusted for parent study, study
centre, patient’s age and length of time on letrozole) were applied.
The relationship between BMI and plasma oestrogen levels was
assessed by Spearman’s rank correlation. The software STATA/IC
11.1 (StataCorp LP, College Station, TX, USA) for Windows was
utilised for statistics. A two-sided value of Po0.05 was considered
as statistically significant.
RESULTS
Oestrone sulphate plasma levels and BMI values were evaluated in
370 patients treated with letrozole for at least 6 weeks, that is, at the
time of letrozole steady state (Lønning et al, 2003), and enrolled in
GIM4 (194 patients) and GIM5 (176 patients) studies. The
individual values of circulating ES in respect with BMI are shown
in Figure 1. Patient characteristics are reported in Table 1.
Values of BMI were the following: BMI o25.0 kgm 2 in 150
patients (40.5%); BMI from 25.0 to 29.9 kgm 2 in 154 (41.6%)
patients; BMI from 30.0 to 34.9 kgm 2 in 50 (13.5%) patients and
BMI X35.0 kgm 2 in 16 (4.3%) patients.
Median age of patients was 60 (range: 34–84 years). No
differences between the four groups were observed: median age 56
(range 34–78), 62 (44–84), 63 (48–78) and 57 (47–78), from the
lower to the higher BMI group, respectively. Five patients in BMI
group o25.0 kgm 2 and two in group 25.0–29.9 kgm 2 resulted
under the age of 45 years.
Median duration of treatment with letrozole was 53 weeks
(range: 6–218 weeks). There was no difference in timing of plasma
sample collection between the different BMI groups: 52 (6–218), 54
(6–197), 52 (6–213) and 55 (6–187) weeks.
Plasma ES geometric means (95% confidence interval) were
58.6 pM l 1 (51.0–67.2) in the group of patients with BMI
o25.0 kgm 2, 65.6 pM l 1 (57.8–74.6) in patients from 25.0 to
29.9 kgm 2, 59.3 pM l 1 (47.1–74.6) in patients from 30.0 to
34.9 kgm 2 and 43.3 pM l 1 (23.0–81.7) in patients with BMI
higher than 35.0 kgm 2 (Table 2).
Plasma ES levels resulted below the sensitivity limit in thirteen
(3%) patients: six, five, one and one, from the lower to the higher
BMI group, respectively.
Oestrogenic concentrations were similar in the different groups
of BMI. The ANOVA (P¼ 0.244) and ANCOVA (P40.102) tests
did not show any statistically significant difference between the
geometric means observed in the different BMI groups.
No correlation between BMI and circulating ES concentration
was found by Spearman’s rank correlation test (Spearman’s rho¼
 0.008, P¼ 0.878).
DISCUSSION
Our study evaluated the circulating concentrations of ES during
letrozole treatment at the standard dose of 2.5mg day 1 in
patients with different BMI.
Oestrone sulphate levels were evaluated as a surrogate of
circulating oestrogens. Oestrogenic concentrations were similar
between the different groups of BMI. No correlations were
observed between BMI and ES plasma levels during letrozole
treatment.
Letrozole plasma concentrations were not assessed to evaluate
compliance, but patients were questioned to confirm compliance
and the number of tablets was accounted for at each follow-up visit
(assessed every 3 months).
Three recent publications evaluated the influence of BMI on
aromatase inhibitors activity.
Diorio et al (2012) compared oestradiol levels in postmeno-
pausal women treated with anastrozole, letrozole or exemestane.
Women were divided according to their BMI (30 patients
o25 kgm 2 and 30 patients 430 kgm 2) and matched for age.
According to results of us, no association was observed between
oestradiol plasma levels and BMI in women treated with aromatase
inhibitors. Oestradiol levels were similar in thin and obese women
treated with aromatase inhibitors (P¼ 0.76).
Similar data were reported in a very recent paper (Pfeiler et al,
2013); after 3 months of aromatase inhibitors treatment, oestradiol
levels of 28 patients with BMIX30.0 kgm 2 were not significantly
higher compared with 40 patients with BMI o29.9 kgm 2
(P¼ 0.1).
Folkerd et al (2012) evaluated plasma oestradiol and ES levels in
a crossover study (ALIQUOT) on 44 postmenopausal patients
treated with anastrozole (1mg per day) for 3 months followed by
letrozole (2.5mg per day) for 3 months or the opposite sequence.
They found a weak correlation between BMI and circulating levels
of oestrogens in patients treated with letrozole (r¼ 0.35; P¼ 0.013,
and r¼ 0.30; P¼ 0.035 for oestradiol and ES, respectively) but no
correlation in the same group when treated with anastrozole
(Folkerd et al, 2012). Mean ES concentrations, during letrozole
treatment, were lower in the o25 kgm 2 group (13 pM l 1), but
similar among 25–29, 30–35 and 435 BMI groups (mean 22, 35
and 25 pM l 1, respectively). When women received anastrozole
mean oestrogen sulfate concentrations were similar among all
groups (mean 44, 62, 66 and 68 pM l 1, respectively). Noteworthy,
in the study of Folkerd, in all groups of patients the absolute levels
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Figure 1. Scatter plot of plasma oestrone sulphate circulating
concentrations (pM l1) according to body mass index (kgm2), in
370 women treated with letrozole.
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of both oestradiol and ES were much lower during aromatase
inhibitor treatment than pretreatment levels. The rates of
oestrogen suppression achieved with aromatase inhibitors in obese
patients were very high (about 98% for letrozole and 96% for
anastrozole) and similar to those obtained in thin patients (Ligibel
and Winer, 2012), thus suggesting that higher than standard doses
of these drugs in obese women are unlikely to lead to a more
complete oestrogen suppression.
In our study, we evaluated oestrogen synthesis by the
assessment of ES levels because they can be considered as a good
surrogate of circulating oestrogens (Lønning and Ekse, 1995).
In fact, oestradiol and oestrone plasma levels in postmenopausal
women treated with aromatase inhibitors could be very low and
undetectable (Geisler et al, 2002, 2008; Dixon et al, 2008), and a
major problem in evaluating the biochemical activity of aromatase
inhibitors in vivo is the assay method sensitivity.
Despite the potential limitation of the oestrogen level assay
methods, our study, the study of Diorio et al and that of Pfeiler
et al suggest that the potential impact of obesity on recurrence risk
in women treated with aromatase inhibitors may not be related to
an incomplete aromatase inhibition in obese women. Because in
postmenopausal women the extent of aromatisation of androgens
to oestrogens is a function of body weight (Edman et al, 1978;
Edman and MacDonald, 1978), it was hypothesised that in
overweight/obese women extraglandular aromatisation from
adipose tissue is not suppressed enough by the standard dose of
aromatase inhibitors with a consequent reduced activity of
these drugs in obese women. Such a hypothesis is not supported
by our data.
Data from studies evaluating the relationship between clinical
outcome and BMI in both advanced and early breast cancer treated
with aromatase inhibitor-based endocrine therapy are conflicting.
In advanced breast cancer, Schmid et al (2000) found that obese
patients treated with letrozole benefited significantly less from
letrozole treatment than those with a lower BMI. In contrast,
Michaud et al (2002) found that the efficacy of anastrozole did not
depend on BMI.
In the adjuvant setting, Sestak et al (2010) investigated the role
of BMI in the relative benefit of the adjuvant treatment with
anastrozole or tamoxifen within the randomised double-blind
Arimidex, Tamoxifen Alone or in Combination (ATAC) trial.
After a median follow-up of 100 months, women obese at baseline
had a significantly higher rate of breast cancer recurrences
compared with non-obese women. The treatment with anastrozole
was associated with a lower recurrence rate as compared with
tamoxifen, regardless of the BMI, but its benefit was greater in
thinner women (Sestak et al, 2010).
The subgroup analysis of the German BRENDA cohort
investigated the correlation between BMI, recurrence-free survival
and adjuvant endocrine therapy. A significantly shorter recur-
rence-free survival was seen in postmenopausal obese patients and
hormone receptor-positive postmenopausal patients with normal
or intermediate weight showed a statistically non-significant trend
towards a survival benefit for aromatase inhibitors compared with
tamoxifen, while obese patients tended to benefit more from
tamoxifen (Wolters et al, 2012).
In contrast to previous reports, data from the TEAM trial
showed no differences in disease recurrences between obese
women treated with tamoxifen and those treated with exemestane
(Seynaeve et al, 2010). Finally, recent data from the Breast
International Group 1–98 Trial indicated that, even though obesity
was an independent adverse prognostic factor for death after breast
cancer, letrozole clinical efficacy was not associated with BMI
(Ewertz et al, 2012).
The relationship between obesity and breast cancer is quite
complex. A recent meta-analysis demonstrated that the association
between obesity and poor overall survival is similar in hormone
receptor-positive and hormone receptor-negative breast cancer
patients (Niraula et al, 2012). Pathways not related to sex
hormones (insulin, Goodwin et al, 2002 or related proteins,
Duggan et al, 2011; Irwin et al, 2011; insulin-like growth factor
signalling pathways, Renehan et al, 2006; adipokines or growth
factors secreted by adipose stromal cells from endogenous adipose
tissue, Zhang et al, 2012) may contribute to the effects of obesity on
breast cancer clinical outcomes.
Table 1. Patient characteristics
Characteristics
Global
(N¼370)
BMIo25.0
(N¼150)
BMI 25.0–29.9
(N¼154)
BMI 30.0–34.9
(N¼50)
BMIX35.0
(N¼16)
Median age, years (range) 60 (34–84) 56 (34–78) 62 (44–84) 63 (48–78) 57 (47–78)
Mean weight, kg (s.d.) 68 (11) 59 (6) 70 (6) 80 (8) 95 (13)
Mean height, m (s.d.) 1.61 (0.06) 1.62 (0.06) 1.61 (0.06) 1.59 (0.06) 1.57 (0.06)
Mean BMI, kgm2 (s.d.) 26.3 (4.4) 22.4 (1.9) 27.1 (1.4) 31.7 (1.4) 38.4 (3.7)
Age, N (%)
o50 37 (10) 23 (15) 9 (6) 2 (4) 3 (19)
50–55 75 (20) 41 (27) 25 (16) 5 (10) 4 (25)
455 258 (70) 86 (57) 120 (78) 43 (86) 9 (56)
Median Let duration, weeks (range) 53 (6–218) 52 (6–218) 54 (6–197) 52 (6–213) 55 (6–187)
Clinical trial, N (%)
GIM4 194 (52) 83 (55) 79 (51) 24 (48) 8 (50)
GIM5 176 (48) 67 (45) 75 (49) 26 (52) 8 (50)
Abbreviations: BMI¼body mass index; GIM¼Gruppo Italiano Mammella; Let¼ letrozole; N¼ number of patients; s.d.¼ standard deviation.
Table 2. Plasma oestrone sulphate geometric means
Body mass
index (kgm2)
Number
of patients %
Oestrone
Sulphate
geometric
mean
(pM l1)
95%
Confidence
interval
o25.0 150 40.5 58.6 51.0–67.2
25.0–29.9 154 41.6 65.6 57.8–74.6
30.0–34.9 50 13.5 59.3 47.1–74.6
X35.0 16 4.3 43.3 23.0–81.7
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In conclusion, our results show that increased BMI does not
affect the ability of letrozole in suppressing endogenous levels of
oestrogens, evaluated by ES assessment. Mechanisms other than
the high oestrogen synthesis could contribute to the poorer
prognosis observed in obese breast cancer patients.
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